Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...
For patients undergoing a radical cystectomy, staying active before and after surgery is key, Dr. Janet Kukreja explained. For patients with bladder cancer undergoing radical cystectomy (the surgical ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...
2025 DEC 31 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Managed Care have been published. According to news reporting out of San Francisco, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback